262 related articles for article (PubMed ID: 31661652)
1. Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimer's disease: Where do we stand?
Veerabhadrappa B; Delaby C; Hirtz C; Vialaret J; Alcolea D; Lleó A; Fortea J; Santosh MS; Choubey S; Lehmann S
Crit Rev Clin Lab Sci; 2020 Mar; 57(2):99-113. PubMed ID: 31661652
[TBL] [Abstract][Full Text] [Related]
2. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein.
Marksteiner J; Hinterhuber H; Humpel C
Drugs Today (Barc); 2007 Jun; 43(6):423-31. PubMed ID: 17612711
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis of Alzheimer's disease utilizing amyloid and tau as fluid biomarkers.
Lee JC; Kim SJ; Hong S; Kim Y
Exp Mol Med; 2019 May; 51(5):1-10. PubMed ID: 31073121
[TBL] [Abstract][Full Text] [Related]
5. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S
Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249
[TBL] [Abstract][Full Text] [Related]
6. Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study.
Pérez-Grijalba V; Romero J; Pesini P; Sarasa L; Monleón I; San-José I; Arbizu J; Martínez-Lage P; Munuera J; Ruiz A; Tárraga L; Boada M; Sarasa M
J Prev Alzheimers Dis; 2019; 6(1):34-41. PubMed ID: 30569084
[TBL] [Abstract][Full Text] [Related]
7. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.
Blennow K; Hampel H; Weiner M; Zetterberg H
Nat Rev Neurol; 2010 Mar; 6(3):131-44. PubMed ID: 20157306
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of fluid biomarkers in Alzheimer's Disease.
Lewczuk P; Łukaszewicz-Zając M; Mroczko P; Kornhuber J
Pharmacol Rep; 2020 Jun; 72(3):528-542. PubMed ID: 32385624
[TBL] [Abstract][Full Text] [Related]
10. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
[TBL] [Abstract][Full Text] [Related]
12. Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies.
Mattsson-Carlgren N; Palmqvist S; Blennow K; Hansson O
Nat Commun; 2020 Dec; 11(1):6252. PubMed ID: 33288742
[TBL] [Abstract][Full Text] [Related]
13. Identifying and validating biomarkers for Alzheimer's disease.
Humpel C
Trends Biotechnol; 2011 Jan; 29(1):26-32. PubMed ID: 20971518
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
[TBL] [Abstract][Full Text] [Related]
15. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C
J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478
[TBL] [Abstract][Full Text] [Related]
16. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
17. Influence of Allergy on Immunoglobulins and Amyloid-β in the Cerebrospinal Fluid of Patients with Alzheimer's Disease.
Sarlus H; Eyjolfsdottir H; Eriksdotter M; Oprica M; Schultzberg M
J Alzheimers Dis; 2015; 48(2):495-505. PubMed ID: 26402013
[TBL] [Abstract][Full Text] [Related]
18. [Molecular markers of Alzheimer disease early diagnostic: investigation perspectives of peripheral tissues.].
Paltsev MA; Zuev VA; Kozhevnikova EO; Linkova NS; Kvetnaia TV; Polyakova VO; Kvetnoy IM
Adv Gerontol; 2017; 30(6):809-817. PubMed ID: 29608821
[TBL] [Abstract][Full Text] [Related]
19. Laboratory biomarkers in Alzheimer's disease.
Steinerman JR; Honig LS
Curr Neurol Neurosci Rep; 2007 Sep; 7(5):381-7. PubMed ID: 17764627
[TBL] [Abstract][Full Text] [Related]
20. CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42.
Andreasen N; Sjögren M; Blennow K
World J Biol Psychiatry; 2003 Oct; 4(4):147-55. PubMed ID: 14608585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
